NUCB2 and type 2 diabetes mellitus: However, subgroup analysis revealed higher nesfatin-1 concentrations in newly diagnosed type 2 diabetes patients (2.01 (0.64) vs. 1.35 (0.43) μg/L and 1.91 (0.79) vs. 1.41 (0.58) μg/L), and significantly lower nesfatin-1 concentrations in type 2 diabetes patients receiving antidiabetic treatment (1.26 (0.319) vs. 1.51 (0.467) μg/L, and 0.99 (0.548) vs. 1.48 (0.816) μg/L).